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1. Introduction
1.1. Tumor suppressor genes, a historical perspective
Cancer is essentially considered to be a genetic disease caused by the accumulation of multiple
genetic or epigenetic lesions in tumor-suppressor genes and oncogenes [1]. Although the
notion that retinoblastoma could be an inherited disease was already formulated at the end of
the 19th Century, a solid genetic basis was established with the discovery of both proto-
oncogenes, whose gain-of function mutations or altered expression is associated with the
cancerous state, and tumor suppressor genes (TSGs), whose inactivation releases the “brakes”
inhibiting cell proliferation. Analysis of both proto-oncogenes and TSGs revealed also that
cancer results from an alteration of the normal pathway of cell fate and differentiation. The
hallmarks of cancer, as laid down by Hanahan and Weinberg to explain the complex biology
of cancer, comprise of six major developmental changes taking successively place in human
tumors. These cancer “characteristics” include sustained proliferative signaling, evasion of
growth suppressors, resistance to cell death, replicative immortality, angiogenesis as well as
cell invasion and metastasis. Underlying these hallmarks are genome instability, inflamma‐
tion, reprogramming of energy metabolism and evading immune destruction [2].
Cancer cells are the foundation of the cancer disease, as they initiate formation of tumors and
drive tumor progression forward. Based on the sequence of events in which cells accumulate
genetic lesions, tumor progression and metastasis are highly variable, even among tumors of
the same type [3]. Previously, cancer cells within tumors were thought to be largely made of
homogenous cells until relatively late in the course of tumor progression, when hyperprolif‐
eration combined with increased genetic instability spawn distinct clonal populations. Now
we know that tumors rather than homogenous masses of proliferating cancer cells are complex
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tissues composed of distinct cell types, participating in heterotypic interactions with each
another. Reflecting such clonal heterogeneity is the finding that many human tumors display
a complex histological pattern, characterized by regions exhibiting various degrees of differ‐
entiation, proliferation, vascularity, inflammation and invasiveness [2]. In addition, tumors
exhibit another dimension of complexity arising from the surrounding normal cells of the
“tumor microenvironment” [2] (analyzed in part 3).
Over the last decades the origin of oncogenesis has been the subject of different theoretical
“fashions”. In the current view taking into account the role of oncogenes and tumor suppressor
genes, cancer results from a failure occurring more in the control of cell differentiation than in
cell proliferation [4, 5]. Nowadays, cancer is generally considered to result from a block or an
error in the normal progression of differentiation. As a result, the cancer cells escape the
mechanisms controlling normal growth and proliferation. Several decades ago, pioneer
studies in the field of Drosophila, mouse somatic cells and human genetics revealed that
neoplasia may result from a loss of function in regulatory genes controlling cell growth and
differentiation [6-9]. In the following years, research in developmental biology has greatly
contributed to cancer research. Indeed very often the initiating event in the formation of a
malignant tumor is a block of a critical step in normal differentiation, usually through
inactivation of a single gene, and can be accompanied by events occurring in parallel. In the
case of tumor-suppressor genes, proliferation of tumor cells is suppressed by the same set of
genes that suppress the proliferation of normal cells, in the same cell type during the process
of differentiation. Studies of the Drosophila lethal [2] giant larvae (lgl) gene, the first cloned tumor
suppressor gene, have shown beyond doubt that tumors can be produced at a defined period
of development by the impairment of a gene that normally regulates a critical step of differ‐
entiation [5, 10, 11]. At that time, such precise time delimitation in the process of development
would not have been possible to achieve with mammalian cells, but the observations made
thereafter in mammals were consistent with the conclusion derived from the Drosophila study.
1.2. Identification of the first tumor suppressor genes in Drosophila melanogaster
Over the past 40 years it has become increasingly evident that cancer is causally related to
mutations in specific genes. These genes are instrumental to developmental processes such as
cell-cell communication, signal transduction, regulation of gene expression, translation,
cytoskeletal organization, protein folding and transport, and differential regulation of cell
cycle [12]. The Drosophila field has made marked contributions in many of the mechanisms
that are fundamental to cancer processes, several of which have been later validated in
vertebrates. Less well known is the precursor role of Drosophila in the cancer field, as some of
the earliest tumor suppressors were identified in flies. The first tumor-containing mutant was
recognized in 1967 in a wild type laboratory stock of Drosophila melanogaster [6]. The mutant
gene was soon identified by Ed Lewis as an allele of the already known lgl gene, which was
discovered by Bridges in 1933 [13]. During the 1940-50s, this gene has been the subject of a
number of developmental studies performed by Hadorn and his collaborators. The phenotypic
studies performed by Hadorn’s group on lgl and other Drosophila genes have greatly contrib‐
uted to the conceptual basis of developmental genetics. In 1955 Hadorn published in German
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his seminal monography on “Lethalfaktoren und ihrer Bedeutung für Erbpathologie und Genphy‐
siologie der Entwicklung” which in 1961 was translated into English as “Developmental Genetics
and Lethal Factors”. Comparative developmental studies conducted thereafter showed that one
of the pleiotropic effects of the mutation was the formation of a malignant neuroblastoma in
the larval brain and the appearance of imaginal disc tumors [7, 14]. Molecular studies on the
lgl gene were initiated in 1985 by Mechler and his co-workers by cloning the first tumor
suppressor gene [10]. Subsequent analysis of lgl has demonstrated unequivocally that the
tumorous phenotype results from the lack of lgl function and showed that tumorigenesis can
be rescued by reintegrating a wild type copy of lgl into the genome of lgl-deficient animals [15].
Biochemical and genetic analysis of the lgl gene and its human homologue hugl-1, showed that
the encoded proteins are components of the cytoskeleton and interact physically with a domain
located near the carboxyl terminal of the non-muscle myosin II heavy chain [11, 16-20]. Further
studies also revealed that the Lgl protein can interact with the Nucleosome Assembly Protein-1
(NAP-1), a component of the cyclinB-p34cdc2 kinase complex [21, 22] and NAP-1 is intimately
associated with the cytoskeletal matrix during interphase and accumulates in the nucleus
during prophase where it becomes associated with the spindle apparatus [21].
Recent contributions show that the Lgl protein may directly contribute to genetic regulation
in association with the heavy chain of nonmuscle myosin II, or nmMHC II [23, 24]. In particular
mutations in lgl or heteroallelic combinations between lgl and zipper, encoding nmMHC, were
found to block the disintegration of the salivary glands by blocking the program induced by
the molting hormone ecdysone [23]. An interaction between both proteins was found to be
required for the binding of specific nuclear remodeling proteins to chromatin [24]. Defect in
this interaction may result in a block of genetic cascade initiated by the ecdysone hormone and
lead to a transcriptionally frozen genome. The outcome of these analyses shed light on the key
roles that tumor suppressor genes may play not only in the mechanism of cell shape and tissue
organization but also in the regulation of developmental programs.
Subsequently to these initial studies, Gateff isolated a series of other recessive mutations in
distinct genetic loci, which gave rise to four specific types of tumors. These tumors affected
either the developing larval brain, the imaginal discs, the hematopoietic organs, or the germ
cells [25, 26]. Shortly after lgl was reported [6], a genetic screen assaying imaginal disc
morphology identified a mutation in the discs large (dlg) gene, coding for a septate junction
tumor suppressor gene [27] with a second mutation identified few years later [28]. Twenty
years later, a third mutation with the strikingly similar phenotypes, called scribble (scrib), was
independently isolated in two different labs. Initially scrib was found in a screen for regulators
of epithelial architecture [29]. Parallel to this investigation, a P-element mutagenesis screen led
to the identification of the recessive scribvartul mutation causing late larval lethality, imaginal
disc overgrowth and brain tumors with a complex syndrome reminiscent of that observed in
mutations of the other tumor suppressors [30]. Therefore, already at the very early days of
tumor genetics, Drosophila has been an extremely favorable object of study. Since then a great
number of tumor suppressor genes have been identified and Drosophila has largely contributed
to our understanding of the basic biology and cellular mechanisms of tumorigenesis including
cell growth and proliferation, apoptosis, maintenance of cell polarity and architecture.
Modeling Tumorigenesis in Drosophila: Current Advances and Future Perspectives
http://dx.doi.org/10.5772/55686
99
Figure 1. Size comparison between wild type 3rd instar larvae and scrib, l(2)gl and dlg giant larvae.
2. Drosophila as a unique model system to study tumor suppression
In order for an animal species to serve as a model of human biology it must fulfill two key
criteria. The model system should be amenable to a broad set of experimental approaches and
to be similar enough to humans so that findings from the model system can be exported to
higher organisms and facilitate research in humans. Drosophila, being at the forefront of genetic
research for the past one hundred years, together with the high degree of conservation with
humans at the gene and cellular level, has proved itself as an essential partner in discoveries
related to genetics, cell biology, human disease and cancer metastasis.
There are also many technical advantages in using Drosophila over vertebrate models. Flies are
easy and inexpensive to culture in laboratory conditions, have a much shorter life cycle,
produce large number of offsprings with feature-rich morphology and large numbers of
externally laid embryos that can be genetically modified in numerous ways. Each female fly
lay up to approximately 50 to 100 eggs per day for up to 20 days. It takes approximately 10
days at 25oC for an embryo to develop into a fertile adult fly. Thus, it is easy to generate large
numbers of embryos or flies for experimental studies and genome-wide screens. Moreover,
there are generally few limited restrictions on their use in the laboratory as there are minimal
ethical and safety issues [31, 32].
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2.1. Drosophila in a century of “tool-building” research
The first documented use of Drosophila in the laboratory was in William Castle’s group at
Harvard in 1901, but the “father” of Drosophila research is without doubt Thomas Hunt Morgan
[33]. It was almost 100 years ago that Thomas Hunt Morgan reported the identification of the
white gene in Drosophila [34]. Morgan greatly refined the theory of inheritance first proposed
by Gregor Mendel, by using Drosophila to define genes and establish that they are found within
chromosomes, long before it was even established that the DNA is the genetic material [31,
35]. Morgan won the Nobel Prize in Physiology or Medicine in 1933 “for his discoveries
concerning the role played by the chromosome in heredity”. One of Morgan’s students,
Hermann Muller, won the Nobel Prize in Physiology or Medicine in 1945 “for the discovery
of the production of mutations by means of x-ray irradiation”. Using Drosophila in 1920s, Muller
discovered that x-rays cause massive increase in the rate of mutations and that the mutations
can be passed from one generation to the other [36]. The genetic approaches used in the first
50 years of research in Drosophila (1910-1960), led to the development of important concepts
and tools e.g. balancer chromosomes, that allowed the study of many other biological processes
in the years to come [35, 37].
Interestingly, researches realized in the early fifties that genetic approaches could be used to
study problems other than heredity. The continuous development of research tools between
the years 1960-2010 has driven numerous new discoveries in fruit flies. In the mid-seventies,
the available genetic tools in Drosophila offered the opportunity to address how embryonic
pattern formation is controlled and to identify the genes involved in these processes [37, 38].
By carrying out a systematic chemical mutagenesis screen on the different fly chromosomes
and analyzing the larval cuticle patterns, Nüsslein-Volhard and Wieschaus identified 139
genes that affect the development of the fly larva [39-41]. This analysis led to the identification
of numerous genes participating in the Hedgehog, Wingless, Decapentaplegic (the Drosophi‐
la Tumour growth factor-β; TGF-β), and Notch pathways. In 1995, Christiane Nüsslein-
Volhard, Eric Wieschaus and Ed Lewis won the Nobel Prize in Physiology or Medicine “for
their discoveries concerning the control of early embryonic development”. These findings have
clearly demonstrated the power of forward genetics in solving complex developmental
questions. Further genetic screens shed light on factors involved in various developmental
aspects such as neuronal migration and growth cone guidance, circadian rhythms, learning
and memory [37]. All these studies proved that despite the great morphological differences
between flies and humans, many of the underlying building blocks and cellular processes are
strikingly similar and conserved through evolution [31].
The range of genetic tools that have become available for Drosophila over the past century
surpass by far those of any other multicellular organism [31]. Two experimental key features,
namely the successful and efficient removal or addition of single genes or gene products, are
important for any model organism to be successfully used in the laboratory. In Drosophila,
genes can be inactivated in a random fashion using chemical mutagenesis followed by
screening for specific phenotypes. Current tools allow very rapid mapping of chemically
induced mutations that have robust phenotypes, permitting the isolation of null alleles,
hypomorphs, neomorphs as well as conditional alleles, making possible the functional analysis
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of single genes. These screens, combined with duplications and deletions covering almost all
chromosomes, have greatly facilitated gene mapping. The recent improvements in whole
genome sequencing techniques and single-cell profiling will enhance even more the speed of
accessibility to genomic information [37, 42]. Apart from the imprecise excision of transposable
elements [43], one can create mutations by selective removal or replacement of sequences using
the “targeted-knockout” technology [44], as well as by using RNA interference (RNAi) to
reduce expression on any gene in a tightly regulated temporal and spatial pattern [45, 46].
The use of P-element-mediated transformation, available since 1982 [47] has allowed the
insertion of single genes and any DNA fragment of interest in the fly genome, and has opened
the field to even more sophisticated genetic manipulations [37]. This technique was signifi‐
cantly improved with the P[acman] technology that allows the insertion DNA fragments in
specific docking sites spread throughout the Drosophila genome [48, 49]. Efficient transforma‐
tion has been achieved by using the Flipase-Flipase Recognition Target (FLP-FRT) recombi‐
nation system, which enables the creation of mutant patches of tissues or cells in an otherwise
heterozygous background [50, 51]. This system led to the development of a highly efficient
“mitotic recombination system” that knockouts defined genetic functions in specific cells,
tissues and organs. The yeast site-specific recombinase FLP, coupled with centromere-linked
insertions of the FRT target site on all major chromosome arms of Drosophila [52], allows the
generation of genetic mosaics, within an otherwise wild type organism, by removing almost
every fly gene function. Generation of genetic mosaics is particularly useful for elucidating the
function of genes which, when mutated, would otherwise kill the organism and subsequently
laid the carpet in understanding how cells within tumors can interact with their surrounding
microenvironment. A considerable improvement of the FLP-FRT system for analyzing mosaic
tissue was the development of the MARCM (Mosaic Analysis with Repressible Cell Marker)
technique [53]. Prior to the introduction of MARCM, homozygous mutant cells were identified
by the absence of a visible marker such as GFP or lacZ in comparison to the surrounding
heterozygous environment and the wild type “twin clone”. By using the MARCM technique
the homozygous clones can be positively marked using e.g. GFP or RFP, which can be of
particular importance for the analysis of single cells in a disease model.
Another use of the P-element-mediated transformation facilitated the development of the
UAS-GAL4 system in order to ectopically express or overexpress a gene of interest in almost
any tissue or cell [54]. The binary UAS-GAL4 system allows a gene DNA sequence fused to the
UAS (upstream activating sequence) to be ectopically expressed via the enhancer/ promoter
of a second gene that drives synthesis of the UAS-binding GAL4 transcription factor. Thou‐
sands of UAS and GAL4 fly lines are now available and their use can either modify or even
abrogate gene expression in selected cell populations, in a specific temporal and spatial pattern
[37, 55, 56]. Moreover, the “Vienna Drosophila RNAi Center” and “Bloomington Stock Center”
house a collection of transgenic fly lines carrying inducible UAS-RNAi constructs against single
protein coding genes. Currently they accommodate over 22.000 different transgenic lines,
which provide knockdowns for over 90% of Drosophila genes. Further development of the
UAS-GAL4 system led to the TARGET (temporal and regional gene expression targeting)
system, which utilizes a temperature-sensitive form of GAL80 repressor that binds GAL4 and
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blocks its transcription activity at the restrictive temperature, while a shift to a permissive
temperature results in GAL80 losing the ability to bind GAL4 [57, 58].
Finally, P-element technology also allowed the tagging of most genes in vivo e.g. with GFP,
RFP or YFP, permitting sophisticated manipulations in a genomic context [59]. Transgen‐
ic flies containing enhancer-trap or protein-trap versions of individual genes allowing the
analysis of the gene expression pattern and protein localization are available at “FlyTrap”
(http://flytrap.med.yale.edu/index.html) [60-63] and “FlyPROT” (http://www.flyprot.org/
index.php) [64].
2.2. Drosophila is a model system relevant to human biology
While Drosophila has long served as a model for basic biological research, more recently its
potential as a model for unraveling molecular mechanisms of human diseases has become
widely appreciated, and numerous publications and conferences illustrate the use of Droso‐
phila to unravel the mechanisms of human diseases [65-69]. Release of the first sequence of the
Drosophila genome in March 2000 (11 months ahead of the human genome release) allowed
the actual comparison to the human genome. This comparison has greatly consolidated
Drosophila’s legitimacy as a model organism for medical research [31, 70]. The sequence and
annotation are freely available in “Flybase”, an outstanding online database combining all
current knowledge on single Drosophila genes including sequence and expression data,
mutations, interactions and up to date scientific references. Comparative studies have shown
that the molecular mechanisms underlying the development of Drosophila and humans are
highly conserved. Since the Drosophila genome contains functional homologues of nearly 75%
of the human disease genes, we can understand why this aspect of Drosophila research
continuously expands. Moreover, over 85% of human genes that have been associated with a
disease, have a Drosophila counterpart. These findings constitute a strong basis for the contin‐
uous expansion of Drosophila research in relation to human diseases.
What makes Drosophila also practical in the analysis of gene function is the nearly complete
absence of genetic redundancy. The duplication of the vertebrate genome during evolution
has resulted in the occurrence of multiple paralogs, e.g. Hox genes that control the body plan
along the anterior-posterior axis [71], with their subsequent evolution that has generated gene
expansion and diversity in protein function [72, 73]. Genetic expansion means that when
knocking down a gene, other genes or homologues can compensate for its function. Yet, the
extra genes rarely represent novel functions as they simply allow more complex and subtle
regulation of core molecular mechanisms. In this respect, the absence of gene duplication in
Drosophila provides the advantage of elucidating more readily the fundamental function of
single genes, e.g. in tumor development, and then apply it back to vertebrates and humans as
the mechanism is very likely conserved [74]. Indeed, lack of redundancy can expose the
physiologically relevant phenotype of gene homologues.
The similarities between flies and humans are further supported by the fact that components
of signal transduction pathways and the molecular mechanisms involved in specification,
development, cell cycle regulation and human diseases were first identified in flies. The genes,
which have been characterized in flies, were subsequently studied in mice and humans, and
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their names were adopted or adapted from their Drosophila homologues. For example, the
mammalian Notch 1-4 named after the Drosophila Notch (fly wings having a large notch on
the wing), “sonic hedgehog” named after the Drosophila “hedgehog” (round larvae with extra
bristles) and Wnt from the Drosophila “wingless and INT-related” gene [31].
3. Recent advances in modeling tumor progression and metastasis in
Drosophila melanogaster
Since the discovery of oncogenes and tumor suppressor genes, intense research in many
laboratories all over the world has brought us to the point where we are starting to understand
the main principles underlying molecular changes in the course of tumor progression [3, 75].
The development of new technologies revealed the complex molecular nature of tumorigenesis
in which tumor progression can be envisaged as a network of simultaneous events within both
tumor cells and the stroma. Because cancer is an age-associated disease in humans, using
Drosophila to model cancer development, progression and metastasis was debatable [76, 77].
However, over the last decades the study of Drosophila has significantly contributed to the
understanding of key cancer events, including the loss of cell polarity, the competition between
tumor and normal cells, as well as metastasis [78].
In addition to the importance of tumor cells themselves, their neighboring cells and the
surrounding stroma are now recognized as important regulators of cancer progression [79].
Cell competition is a type of short-range cell-cell interaction in which cells expressing different
levels of a particular protein are able to discriminate between their relative levels so that the
one cell, the “loser”, disappears from the tissue whereas the other, the “winner”, survives and
proliferates to cover the space left by the disappearing cell. Some tumor-promoting mutations
in Drosophila are able to induce cell competition between the cancer cells and their micro- and
macroenvironment [80-86]. Metastasis is the latest phase of cancer progression during which
cells detach from their original niche to invade distant tissues [87]. For several decades, our
understanding of the molecular processes leading to metastasis was largely derived from
studies of cancer cell lines in vitro, xenografts of human tumors and a limited number of
transgenic or knockout mouse models [1, 88, 89]. However, understanding the individual steps
leading to tumorigenesis or analyzing multiple genetic interactions in mice is difficult. Existing
models are currently being re-evaluated given the increasing awareness of tumor complexity.
Therefore, using a model system that allows the efficient analysis of the combinations of genetic
events that trigger tumor initiation and metastasis during cancer development is the major
challenge in cancer research at the moment. Drosophila melanogaster provides a model of choice
for cancer analysis as the collection of sophisticated genetic manipulation techniques have been
invaluable for dissecting signaling pathways that affect cell specification, differentiation and
growth [90-93]. Indeed, Drosophila cancer models are very helpful in unraveling the chrono‐
logical sequence of events leading to human cancer. For example, in metastasized human
tumors elucidating the identity of the initial mutations is often tedious as oncologists are in
most cases looking at the end point of the disease progression. Finally, Drosophila genetics is
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very powerful as we can dissect the triggering events initiating cancer and the subsequent
steps leading to the progression of the disease [94].
3.1. Modeling cell competition and metastasis
With these added complexities in mind, the analysis of cancer-disposing mutations in only a
subset of cells or in clones within the context of a wild type surrounding tissue is gaining more
interest because it offers a reasonable approximation of the clonal nature of human cancers,
compared to the analysis of the multi-step model of tumor progression in the context of a whole
organism. A great number of very interesting publications provided us with information about
new and unexpected findings on the role of the polarity genes scrib, lgl and dlg in cancer
initiation, progression and metastasis. Nowadays, it becomes obvious that they play a broader
role than initially thought, through the cooperation with individual partners and signaling
pathways and have helped us to understand the role of cell competition and of the tumor
microenvironment during tumor survival and progression.
Analysis of scrib- mutant clones in the Drosophila eye imaginal discs has shown that tumor
development is suppressed by the JNK-mediated apoptotic pathway activated by the sur‐
rounding wild type cells, whereas the neoplastic and metastatic potential is regained through
the synergistic effect of a simultaneous up-regulation of Ras signalling within the same clones
[84, 95, 96]. These results underline the effect of the surrounding normal cells on the trans‐
formed scrib- clonal cells, which leads to a cell competition similar to the one observed in the
mammalian cancers [1, 96-100]. In a model for scrib tumorigenesis, the analysis of the down‐
stream pathways in scrib- epithelial clones revealed that excessive cell proliferation is restrained
by JNK-mediated apoptosis. Upon simultaneous activation of either Ras or Notch, JNK-
mediated apoptosis is blocked, and Ras/Notch together with JNK cooperatively promote
tumor growth and invasion [96]. In other words, whereas JNK activity normally promotes the
apoptosis of scrib-deficient cells, it becomes a driver of cellular overgrowth, tumorigenesis and
invasion in the presence of oncogenically activated Ras or Notch signalling [76, 101]. These
tumors present similar characteristics to human cancers that lack Scrib, including basement
membrane and extracellular matrix degradation, loss of E-cad expression, combined with
migration, invasion and secondary tumor formation [101] Another report provided a molec‐
ular link between loss of polarity and tumorigenesis, since scrib-, dlg- and lgl- clonal cells in a
wild type surrounding become metastatic only in combination with Rasv12 activation, resulting
in JNK activation and E-cad inactivation [102]. The analysis of the JNK-mediated tumorigen‐
esis, which in Drosophila cells reveals a cooperation with Ras similar to that taking place in
mammalian breast epithelial cells, indicates that the knowledge gained from the analysis in
Drosophila can help us elucidate tumor formation in the mammalian system.
Mutations inactivating the Salvator-Warts-Hippo (Sav-Wts-Hpo) pathway can also cause
super-competition, contributing to the overgrowth of cells expressing these mutations in the
presence of wild type cells [80, 103]. Since the first discovery of the Sav-Wts-Hpo pathway in
Drosophila, the role of these genes in restricting cell growth and proliferation, and inducing
apoptosis has triggered a great interest in its study. The components of this pathway act as
important tumor suppressors that regulate tissue growth by promoting cell cycle exit and
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apoptosis [80, 104-112]. Recent data from mammals and Drosophila show the occurrence of a
very conserved pathway that links the pathway of cell polarity to the regulation of tissue
growth.
In the model of Scrib tumorigenesis, induction of apoptosis in scrib clones could not explain
how scrib- cells are prevented from overproliferating. This was answered by the finding that
cell competition between scrib and wild type cells prevents overproliferation by suppressing
Yorkie (Yki; a transcription factor, which is suppressed by the Sav/Wts/Hpo pathway) activity
in scrib- cells [113, 114]. Suppressing Yki activation is critical for scrib- clone elimination by cell
competition. Cell competition leads to activation of JNK in scrib- cells and JNK antagonises Yki
activity, which leads to elimination of the clone. Experimental Yki elevation is sufficient to
promote neoplastic growth in scrib- cells [114]. Along the same line, when lgl is mutated in a
mosaic tissue, the lgl- clonal cells become the “losers” in cell competition. However, simulta‐
neous overexpression of the Ras signalling pathway or of yki in lgl- clones, causes overgrowths
and JNK-mediated apoptosis at the periphery of the transformed clones [115-120]. Moreover,
JNK-mediated elimination of lgl- clonal cells is relieved and the overgrowth potential is re-
established by upregulation of c-Myc, demonstrating the the death of lgl- clones is essentially
driven by c-Myc-induced cell competition [121]. Simultaneous downregulation of the lgl and
the JNK pathway in the whole-animal system results in a phenotypic reversion of tumor
growth, absence of the giant larvae and recurrence of pupariation, thereby showing that JNK
activity is essential for overgrowth and invasion of lgl tumorous discs [122]. Moreover, in the
developing Drosophila eye and imaginal disc epithelia Lgl, αPKC and Crumbs proteins regulate
cell proliferation and survival by controlling the activity of the Sav-Wts-Hpo pathway [115,
123-125].
Among the wide palette of cellular events leading to JNK activation is the dTNF (tumor
necrosis factor)/Eiger. Eiger is the only Drosophila member of the TNF superfamily and its
deregulated expression in imaginal disc cells results in JNK-mediated apoptosis [76, 126]. JNK-
dependent cell death in scrib and dlg clones requires dTNF, acting as a “tumor death factor”
[127]. On the other hand, in tumors deficient for scrib and dlg that also express Ras, the TNF
signal is converted into a signal, which promotes tumor growth and invasion [126]. More
precisely, upon dTNF downregulation, cell death in dlg and scrib clones was blocked and in
situ outgrowths appeared, probably by TNF-mediated extra-cellular matrix (ECM) remodel‐
ling [76, 126]. When generated in an eiger- mutant background, Rasv12scrib- clones displayed
non-invasive in situ overgrowth. Similarly, in whole Rasv12scrib-dTNF- animals, development
proceeded up to pupal stages, overcoming the “giant larvae” phenotype [76, 126]. These recent
results suggest that several of the critical overgrowth phenotypes of scrib, dlg and lgl in the
clonal and whole-tissue context are mediated by dTNF and that dTNF pro-tumor function
depends partially on JNK activation in tumor cells, which provides a switch from in situ to
invasive growth. Immunostaining experiments detected dTNF in a punctuated, intracellular
vesicle pattern at the periphery of hemocytes in association with the dlg- clones, indicating that
dTNF expression in hemocytes is sufficient for dTNF/JNK pathway activation within the dlg-
clones, and mark the importance of hemolymph and non-cell autonomous immune response
in tumor progression [76, 126].
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Until very recently, the mechanism by which surrounding normal tissue exerts antitumor
effects against dlg, scrib or lgl clones remained elucive. New results from clonal analysis in
Drosophila imaginal discs have shown that JNK activation from the wild type surrounding
leads to upregulation of PVR, the Drosophila PDGF/VEGF receptor, that activates the
ELMO/Mbc phagocytic pathway, which in turn eliminates the oncogenic clonal cells by
engulfment [128]. From an evolutionary point of view, the development of such mechanism,
which senses and eliminates “neoplastic” tumor-suppressor mutant cells such as those of scrib-
and dlg- but not “hyperplastic” ones (in which despite of overproliferation, cells are normally
shaped and retain a differentiated epithelial monolayer, such as those of the Hippo pathway
and PTEN) [128], shows the necessity to specifically eliminate the high-risk malignant
neoplastic cells before they confer any harm to the organism. Taken together, these studies
demonstrate that hemocytes together with the tumor microenvironment act as regulators of
epithelial delamination required for tumor invasion. Due to the ease of genetic manipulations,
Drosophila research can bring meaningful insights to our understanding of the mechanisms of
communication between cancerous and normal cells as well as between tumor tissue and the
immune system [87].
3.2. Drosophila provides critical insights on how conserved mechanisms contribute in
cancer and tumorous development
Drosophila research has also contributed to cancer analysis by identifying genes and signaling
pathways later found to be critical for tumorigenesis in mammalian systems. In several cases
Drosophila has been used to establish specific model systems in order to understand processes
that seem to be more complex in vertebrates and mammals [81, 101, 129, 130]. One of the most
extensively studied Drosophila models of tumor biology is the asymmetric cell division of
neuroblasts, the Drosophila neuronal stem cells. In Drosophila neuroblasts (NB), the PAR3-
PAR6-atypical protein kinase C (aPKC) complex segregates apically and recruits the adaptor
protein Inscutable (Insc), which connects this complex to the partner of Insc (Pins), guanine
nucleotide associated protein-α1 (Gα1), mushroom body defect (MUD), and p150glued to the
crescent directing the orientation of the mitotic spindle during asymmetric cell divisions. aPKC
promotes the exclusion of partner of numb (PON), Lgl and Numb, which along with Miranda
(Mira), Brain Tumor (Brat) and Prospero (Pros), localize to the basal crescents [101, 130, 131].
Interestingly, most of these genes have functional mammalian homologues and a very recent
study points out the role of the Par3 in mammalian skin tumorigenesis [132]. In mouse skin
tumorigenesis, Par3 deficiency results in reduced papilloma formation and growth. Further‐
more, Par3 expression is reduced in both mouse and human keratoacanthomas, indicating the
tumor-suppressive properties of Par3. More insights into tumor physiology came from a very
interesting study in Drosophila NBs that indicates the critical role of starvation in promoting
the overgrowth of pins larval brains. Energy stress, mediated by loss of TOR and Phosphati‐
dylinositol 3-kinase (PI3K) components, in combination with loss of pins results in loss of
asymmetric NB division and brain overgrowth (Rossi, 2012). Since the PI3K and TOR signaling
pathways are vital to the growth and survival of mammalian cancers [133, 134], using
Drosophila in order to dissect the cross talk of these pathways to preexisting tumor suscepti‐
bility defects e.g. polarity defects, in a simple animal model is of great importance.
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The usefulness of Drosophila is further illustrated in the development of a Drosophila model for
human brain cancer. Glioblastoma (GMB) is the most frequent and malignant form of high-
grade glioma that infiltrate the brain, grow rapidly and are refractory to current therapies
[135]. One key to development of new and effective therapies against these tumors is to
understand the fundamental genetic, cellular and molecular logic underlying gliomagenesis.
Signature genetic lesions in glioblastomas include mutation of the epidermal growth factor
receptor tyrosine kinase (EGFR) and mutations activating components of the PI3K pathway.
Drosophila studies using lineage analysis combined with cell-type specific markers demon‐
strated that EGFR-Ras and PI3K can induce fly glial neoplasia through activation of a combi‐
natorial genetic network composed in part of other genetic pathways also commonly mutated
in human glioblastomas [135]. In the future, large-scale forward genetic screens with this
model may reveal new insights into the origins of glioblastoma and may also provide new
therapeutic strategy for the treatment of this form of human tumor.
Drosophila has been also used to elucidate the molecular mechanisms of human heredita‐
ry  diffuse  gastric  cancer  (HDGC) [136].  Gastric  cancer,  as  several  human cancers,  origi‐
nates from epithelial cells. Mutations in the CDH1 gene, which encodes the cell adhesion
molecule  E-cadherin  (E-cad),  are  associated with  HDGC in  humans.  In  order  to  under‐
stand the role of E-cad in this disease, a Drosophila  model has been developed in which
mutated forms of E-cad can be studied in vivo [136, 137]. Moreover, genetic and molecu‐
lar  studies  of  Drosophila  hematopoiesis  can  also  contribute  to  our  knowledge  of  the
hematopoietic niche and hematopoietic malignancies in humans. Vertebrate hematopoiet‐
ic stem cells give rise to an hierarchically organized set of progenitors and deregulation of
the  hematopoietic  differentiation  program  can  lead  to  numerous  pathologies  including
leukemias.  With  the  discovery  that  many transcriptional  regulators  and  signaling  path‐
ways controlling blood development are conserved between humans and flies, Drosophila
is particularly suitable model for investigating the mechanisms underlying the generation
of blood cell lineages and blood cell homeostasis [138].
Interesting results using a Drosophila cancer model demonstrated that apoptosis activation in
differentiation-compromised cells constitutes a mechanism for early prevention of cancer
[139]. Apoptosis is a highly conserved cellular function to remove excessive or unstable cells
in diverse developmental processes and disease-responses. An important example is the
elimination of cells unable to differentiate, which have the potential to generate tumors. Using
cell-type specification in Drosophila, Ingrid Lohmann and her colleagues identified a conserved
regulatory mechanism that underlies cell-type specific removal of uncommitted cells by
apoptosis as a cancer prevention mechanism [139]. Under normal conditions the transcription
factor Cut activates differentiation, while it simultaneously represses cell death via the direct
regulation of a pro-apoptotic gene. However, loss of Cut and subsequent release of apoptosis
leads to overproliferation of the mispecified cells that can acquire metastatic potential in a
sensitized background. Importantly, this regulatory wiring is also found in vertebrates in
which other cell-type specification factors may similarly be employed to suppress tumor
formation. Thus, coupling of differentiation and apoptosis by individual transcription factors
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is a widely used and evolutionarily conserved cancer prevention module, which is hard-wired
into the developmental program [139].
Furthermore, genetic analysis of border cell migration in the Drosophila melanogaster ovary
provides clues that improve our understanding of ovarian cancer metastasis at the molecular
level that might also lead to therapeutic targets [140]. The border cells of the Drosophila ovary
provide a particularly simple example of cell migration in which cells derived from an
epithelium invade a neighboring tissue. The large numbers of genes that control border cell
migration identified in genetic screens emphasized also the requirement of multiple extracel‐
lular signals for border cell motility [141]. Interestingly, the motile and invasive properties of
the border cells seem to share common characteristics with mammalian ovarian carcinoma
cells. Based on work done in Drosophila, the function of some mammalian proteins such as
myosin VI, have been tested for their ability to regulate motility of ovarian carcinoma cells.
1 Drosophila flies are easy and inexpensive to culture in laboratory conditions, have relatively low set-up and
maintenance costs
2 Short life cycle
3 High fecundity (produce large number of off-springs with feature-rich morphology)
4 The Drosophila community is open and generous in sharing reagents within the community.
5 No ethical issues and regulatory considerations.
6 Genetic advantages
• flies have only 4 pairs of chromosomes
• males lack genetic recombination, making genetic crosses easier
• flies tend to lack genetic redundancy
7 Signaling pathways controlling growth, differentation and development, which are involved in tumor
formation in the fly are largely conserved between Drosophila and humans
8 Availability of numerous genetic tools & reagents for generating mutants and analysis of gene expression
by using methods producing over- & ectopic- expression.
• The use of “balancer chromosomes” with multiple DNA inversions prevent female recombination and
allows the perdurability of mutations on the original carrier chromosome
• Wide variety of gene targeting strategies, e.g. UAS-GAL4 system combined with RNAi knock-down allow
the tissue-specific analysis of tumor suppressor gene and oncogene function
• Mosaic analysis of animals containing mutant clones next to wild type tissue, using FLP-FRT and MARCM
recombination systems, allows the analysis of tumor microenvironment in invasion, metastasis &
inflammation.
9 Possibility to perform genome-wide screens using chemical mutagenesis, tissue-specific RNAi knockdown,
effectors and modifier screens to identify genes involved in specific developmental pathways and assign
and validate new gene functions.
10 Use of Drosophila tumor models for pharmacological screening and development of new therapeutic
strategies for cancer.
Table 1. Advantages of Drosophila melanogaster for the analysis of cancer.
Modeling Tumorigenesis in Drosophila: Current Advances and Future Perspectives
http://dx.doi.org/10.5772/55686
109
Another example can be found in the EGFR pathway, which functions redundantly to PVR to
stimulate border cell migration [142]. Overexpression of EGFR has been reported in up to 70%
of ovarian carcinomas [143]. The role of E-cad is also here critical. Normal cells of ovarian
surface epithelium express little or no E-cad. However, many primary ovarian carcinomas,
similar to border cells, express E-cad at the cell surface and in the cytoplasm [144, 145].
Although cell-surface expression of E-cad is reduced in many metastatic carcinomas, these
tumors frequently still have detectable intracellular E-cad [146], indicating that these cells,
similar to border cells, have acquired the ability to downregulate E-cad activity at a post-
transcriptional level [140].
Numerous molecules identified in Drosophila genetic screens have proven to be important to
human cancers [140, 147]. For example, the Hedgehog gene and the Wnt homologue Wingless
were originally identified in genetic screens for mutations that disrupt embryonic patterning.
Subsequent studies of signaling proteins such as Hh, Wnt [140, 148-150], Notch [151, 152] and
RhoGTPases [153] as well as of integrin-related adaptor proteins [154, 155] and Hox genes
[156, 157], revealed crucial functions not only in normal mammalian development but also in
various cancers. It is therefore well accepted that genetic approaches to the study of normal
cellular behavior in simple model organisms can yield fundamental insights into the molecular
underpinnings of cancer.
4. New perspectives in modeling tumorigenesis in Drosophila
melanogaster
Drosophila is emerging as a valuable system for use in clinical drug discovery and therapeutic
process [52, 129, 158-160]. So far, Drosophila was not a favorable model in drug discovery. The
main reason was that “Drosophilists” were mainly concerned with answering fundamental
development and cell biology questions, and elucidating principles of basic mechanisms and
not practical issues of therapeutics [129]. This view is slowly changing as interest in therapeu‐
tics and pressure for practical outcomes increases, and combined with the development of
powerful tools allows Drosophila to catch-up in the field.
The remarkable degree in conservation of biochemical pathways that control processes such
as cell proliferation, differentiation and migration as well as nervous system function in
behavior and cognition, sustains perfectly the use of invertebrate model genetic organisms as
tools for drug discovery and validation [52]. Drosophila’s genetic and genomic tools can be
adapted to build sophisticated disease models for studying cancer and metastasis, and for
therapeutic development. While testing with mammalian models is essential prior to approval
for human trials, the use of invertebrate animal models that are amenable to molecular genetic
manipulations, provides experimental and biological advantages that can streamline drug
discovery and testing process. Among the benefits of a genetics-based approach is the ability
to screen for proteins that may be novel drug targets, and in genetic backgrounds that could
more accurately reflect a specific disease state [52]. New drugs can be tested in Drosophila much
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faster than in mammalian models and can even be used for high throughput screening
processes as an alternative to cell culture [31].
Drosophila may constitute an appropriate model system that can be used for screening a “whole
animal setting” as an alternative to cell-cultured based methods. In most pharmaceutical
industries the discovery of new compounds with potential positive pharmacological effect
relies on the screening of small molecule libraries for interactions with purified proteins, or
for the ability to induce a desired physiological response in cultured cells [52]. One of the main
problems is that complex processes such as tumor metastasis cannot be recapitulated in a cell
or an organ culture. Moreover, cells and organs are physiologically connected and their
interplay could be critical in the development of some diseases. Furthermore, the time
component of the disease progression cannot be easily recapitulated in vitro [161]. The second
problem is that after the initial screen, the next phase of drug testing, which requires the use
of intact mammalian animal models to assay the effectiveness of candidate compounds,
usually fails. If in this step of drug discovery process, the compounds isolated in vitro or in cell
culture, are invalid in mouse, the result is an enormous waste of funds and efforts [158]. At
the same time, whole animal vertebrate models are not particularly suitable for high-through‐
put methodologies and if then only at an extremely high cost. To by pass these limitations,
efforts are now being made to screen chemical libraries on whole-animals like Drosophila with
genetic amenability, low cost and culture conditions compatible with large-scale high-
throughput screening.
Furthermore, performing drug screening in the Drosophila “whole animal system” does not
dependent on the prior identification of a target and permits the selection of compounds with
an improved safety profile. A screen based on a phenotypic observation has the advantage of
being independent of the specific molecular target involved. Then, depending on the readout
used to assay the effectiveness of the candidate drug compound, a large variety of bio-active
molecules may be detected in the same screen [158]. Finally, similar to the established “en‐
hancer” or “suppressor” screens, Drosophila gives the possibility to test chemical libraries in
the genetic background of a disease for their ability to reverse the abnormal phenotype to wild
type or partially rescue the disease phenotype [158, 161].
Several groups today develop the associated technology to use Drosophila in the first phase of
screening for drug compounds, and subsequently test them in more expensive mammalian
models. Moreover, the fact that it is usually easier and more straightforward to manipulate
the genetic background of Drosophila and mimic a disease state, opens also new possibilities
for efficient drug testing in a disease-related content. For example, the development of
genetically modified animals with fluorescently tagged proteins would allow the use of
standard plate-reader spectrofluorometer for whole-animal screens [161].
When the development of mosaic tissues is essential for the analyses of a disease model, the
use of MARCM provides notable advantages for effective drug discovery. One is the ability
to follow the morphology of mutant cells and tissues which could be useful for assessing the
efficacy of a therapeutic compound [52]. When a mutation in a given gene causally produces
a disease, it is possible that this mutation elicits a change in expression of other genes and in
the function of proteins. These alterations may contribute to the pathologies associated with
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the disease. The characterization of these changes constitutes then the first step needed to
develop rational therapeutic strategies. Finally, the MARCM methodology should provide
ways to identify mutant cells or tissues for a given gene, isolate and subject them to proteomic
and genomic analyses which would determine modifications in gene expression and protein
interaction profiles [52].
The phenotypes of complex trait diseases such as obesity, heart disease and cancer are the
result of modifications occurring in multiple biochemical pathways. The disease phenotype
can be caused by improper activation or inhibition of a protein that acts in any of the contri‐
buting pathways. Restoration of the normal phenotype would be expected if the output from
the primary biochemical pathway affected is rescued via drug-based therapy [52]. However,
if multiple pathways contribute to a phenotype, it stands to reason that modifying the activity
of a parallel pathway could also elicit a positive therapeutic effect. The use of genetic model
organisms has long been a successful means for elucidation of biochemical and physiological
pathways, and one of the most powerful strategies available for uncovering genes that act
together in producing a phenotype is a search for genetic interaction or a modifier screen.
Modifier screens work by generating animals with a mutation in a gene of interest that elicits
a sensitized phenotype, and then screening for mutations in progeny that enhance or suppress
(i.e., modify) the primary phenotype [52]. Drosophila disease models are currently used in drug
screening for treatment of diseases such as Alzheimer’s and Huntingtons’s disease, Fragile X
Syndrome and muscular dystrophy [160, 161]. The use of drug discovery especially for muscle
diseases is of particular importance as the muscles are difficult to reconstitute in vitro and
elucidation of the physiology of muscle related diseases and relevant treatment is still poorly
understood. However, the similarity in architecture, composition and function between
Drosophila and vertebrates may trigger studies in the fruit fly and provide these diseases with
some valuable therapeutic answers [161].
Drug discovery has also proved very effective for the identification of cancer treatments such
as the multiple endocrine neoplasia type-2 (MEN2) [129, 162]. MEN2 is a “one-hit” solid tumor
syndrome, characterized by mutations in the Ret protein, a transmembrane receptor tyrosine
kinase. Patients with mutated oncogenic isoforms of Ret, develop medullary thyroid carcino‐
mas (MTC) that lead to metastasis, which seem to be resistant to traditional chemotherapies.
To develop a whole-animal transgenic model, various oncogenic Ret isoforms were targeted
to the developing fly eye epithelium. The fly ”rough-eye” phenotype is characterized by eye
overgrowth, switch in cell fate and other aspects, proving the effectiveness of fly as model and
useful readout for screening. The screening for clinical relevant compounds, in the tumorous
developing flies by Cagan and his group resulted in the identification of Vandetanib, a broad
kinase inhibitor, which Cagan called “the worst kinase inhibitor”. Although not very specific
and effective, this kinase inhibitor was indeed effective in rescuing the fly phenotype because
it regulated the activity of other kinases such as Ras, Src and PI3K (all of which are involved
in cancer). Other compounds were more capable of rescuing the rough eye phenotype but
reduced animal viability. Yet, Vandetanib displayed little toxicity to the animal as a whole,
indicating that tumors might display a lower tolerance threshold for drugs than the entire
animal. Obviously the “off-target” effects of Vandetanib, by suppressing kinases other than
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Ret, are important for its effectiveness. Classical drug screenings would reject Vandetanib as
too inefficient to the target and too low in its specificity [129, 162]. Cell-culture and subsequent
fly work proved to be extremely valuable, as Vandetanib was shown to be efficient in Phase
II clinical trials. Currently Vandetanib is in Phase III of clinical assays. This further proves the
power of Drosophila not only for clinical relevant drug discovery but also for shaping how we
should approach drug discovery for treating diseases.
A new in vivo drug screening in Drosophila has been performed to target cancer stem cells
(CSCs) in the group of Norbert Perrimon [163]. Cancer cells represent a small number of cells
within tumors with a self-renewing capacity that can regenerate tumor cells types through
their stem cell-like renewal capacity. Their resistance to chemotherapy is the main reason why
chemotherapeutic treatments are ineffective and the disease often relapses. In order to cope
with the challenge of finding drugs that specifically target the CSCs, the Perrimon laboratory
uses the Drosophila gut as the stem cell system to develop novel methods and approaches to
screen for anti-cancer drugs that target CSCs in vivo in the gut microenvironment. By directing
the expression of oncogenes in Drosophila transgenic fly models combined with a screening
method that involves monitoring of tumor size by luciferase reporter activity, they identified
25 compounds that reduced tumor size. Further confirmation was validated with dissection
of the gut, histochemical-imaging of the gut specific cells and determination of the specificity
of the drugs. For example, some drugs were targeting only the CSCs whereas others were
targeting CSCs but at the same time promoted growth of the wild type stem cells and in some
cases also affected stress pathways in the daughter cells.
5. Limitations in using Drosophila as a model system: how far can we go?
Drosophila melanogaster, as a model system for studying tumorigenesis and human disease has
certain limitations, especially in regard to the biological processes that evolved only within the
vertebrate lineage [164]. The main limitation of Drosophila arises from the fact that some
diseases cannot be modeled because the corresponding genes and organs present in humans
are missing in flies [161]. For example, Drosophila has a single cardiac chamber that functions
as a heart in the context of an open circulatory system. Moreover, the Drosophila myocardium
receives oxygenation through diffusion and does not have coronary arteries [165]. A second
limitation arises from differences in cellular and molecular processes of Drosophila in compar‐
ison to humans. For example, there are cases in which one or several key molecules mediating
a human disease-specific pathway are missing in flies [160]. Ultimately, some areas such as
learning, endocrine function and mammary gland development, may prove difficult to study
in a simple invertebrate like Drosophila and so the study of these particular disorders may not
benefit substantially from Drosophila genetics [166]. Another example is modeling tumor
metastasis. In mammals malignant cells undergoing metastasis enter the local blood or lymph
vessel before colonizing a distant tissue and forming metastatic tumors. This is very difficult
to model in Drosophila as flies have a rudimentary hematopoietic system and a dramatic
different lymphatic system compared to mammals [78]. However, one should point out that
despite these differences the “master regulators” of heart, eye, kidney etc. have proved to be
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remarkably conserved [162]. This means that in the case of e.g. spinal malformation, flies could
be used to model bone formation per se, but as Notch signaling has a pivotal role in regulating
this process, any knowledge obtained about interactions between components of this pathway
in Drosophila could be relevant to processes that these genes control during spinal formation
in humans [164].
Are there limitations in using Drosophila for treatment-relevant drug discovery? The limita‐
tions in this case result from the anatomical and molecular differences of small model organ‐
isms in comparison to humans, as this may cause the elimination of a significant fraction of
the hits generated. The use of Drosophila models should be viewed as complementary alter‐
natives to cellular assays and in vitro screenings made in mammalian cells, rather than the
absolute shortcut to screen drugs for human treatments [158]. Their added value for drug
discovery varies from disease to disease, and mainly depends on the availability of other
options. Indeed, assays in Drosophila are complementary to in vitro and cellular systems, and
in comparison to rodent model systems Drosophila’s small size and culture conditions fulfill
the requirements for large-scale screens [158]. Furthermore, another limitation also results
from the dose-dependence of the drug treatment. In rodent model systems the drug dosage
may differ according to the mode of penetration and the nature of the drug. In Drosophila dose-
response experiments are easily feasible but the compounds are essentially delivered to the
fruit flies through the media [167]. Thus, it is important that the results obtained with Drosophila
are compared with data obtained on laboratory rodents and, when possible, in humans.
Furthermore, in numerous cases the results will be more qualitative than quantitative.
Although the conclusions derived from Drosophila studies may remain too uncertain for
pharmacologists, the data obtained from invertebrate-based screening could lead to important
breakthrough, particularly for those diseases in which the pathophysiology is poorly under‐
stood [158, 161].
Often model systems are used to understand life and basic biological and cellular mechanisms.
A better understanding of a specific human disease often comes as a consequence of the better
overall understanding of biological processes [159]. Within this context, Drosophila is a valuable
tool to categorize putative candidate genes for further downstream functional analysis in
vertebrates. It can be used to dissect the likelihood that individual genes in a gene-cluster
contribute to disease susceptibility, identify the relevance of a gene to a disease-pathway and
get insights on gene specific functions manifested at the level of a tissue or involving cell-cell
communication. Using Drosophila models, preliminary experiments with other model systems
(such as mice) may be reduced and experiments in higher organisms can be better focused.
Using Drosophila in a systematic approach together with other models and tools, seems
promising in order to significantly reduce the turnout time from genetic results into biologi‐
cally meaningful data [168]. Conclusively, although Drosophila will probably not always serve
as a perfect model for human disease modeling, the common underlying molecular interac‐
tions and signaling pathways between flies and humans will continue to allow researchers to
use Drosophila in order to answer existing questions, pose new hypotheses, get entry points in
elucidating cancer and personalized cancer therapy, and complement studies from other
model systems and vertebrate organisms [164].
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6. The expanding role of Drosophila in cancer research: Bridging past,
present and future
Undeniably the study of Drosophila has brought major contributions in understanding to the
fundamentals of cancer and has further given strong impulses not only in basic but also in
applied research. The unrivalled advantages and tools offered by Drosophila ensure that it will
remain a premier research organism for many years to come. The advantages of Drosophila as
a model system includes the availability of genetic tools developed in a century of “tool-
building” research, its short life cycle and ability to unravel the basic function of genes in a
straightforward way. The use of visible mutations and chromosome mapping coupled to
currently available complex genetic databases including genomic and proteomic sequences,
together with help of systematic gene disruption (RNAi libraries), microarray analysis, protein
interaction maps and Flybase, lay the carpet for a renewed new age of research in Drosophila,
and will allow scientists to address new questions on biological processes which were
previously inaccessible. In turn, the new discoveries will foster new research and answer to
more precise questions about signaling pathways and behavior of individual cells in cancer.
The Drosophila research will continuously contribute to a better understanding of tumor
formation and progression, and may thus improve therapies in treating cancer.
Could Drosophila still be a valid model for understanding tumor formation and could it still
provide a lead for curing cancer? Although the fruit fly does not appear to be suited for
studying vertebrate-specific tissues, such as brain and heart development or neural crest
migration [37], Drosophila may still help to identify critical key-genes, discover new biological
pathways, define new research approaches, and therefore pioneer numerous fields in the
understanding of cancer, including vertebrate biology. Drosophila can also be used to unravel
the sequence of events leading to tumor formation and to trace the initial stages of tumor
formation. One of the main outcomes of the genome analysis has been the finding of a high
degree of conservation among genes and importantly 75% of the genes involved in human
diseases have homologues in Drosophila. There is also a high degree of functional conservation
between the signal transduction pathways and a high degree of structural and functional
conservation between cell adhesion proteins of Drosophila and humans showing that the
fundamental biological processes have a common origin and has been relatively conserved
during the 600 million years of evolutionary divergence between invertebrates and vertebrates.
New emerging challenges in the study of tumorigenic inflammation, in in vivo screening for
drug acting on cancer stem cells, in the therapeutic drug design and discovery will provide us
with new insights into a “multi-target” approach for treating cancer. Finally, innovative
technologies such as microarrays and nanotechnology, combined with novel methods in
computation and bioinformatics, could be used in combination with genome-wide analysis in
Drosophila, functional maps of the chromatin landscape [169-171], cis-regulatory map of the
Drosophila genome and pattern of co-binding partners in transcription [172], as well as high-
resolution of transcriptome dynamics throughout development [173, 174] to define more
accurately the network of genes and pathways that would permit initial cancer cells to build
expanding tumors. These new directions highlight not only the value of basic research but also
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the intrinsic advantages of Drosophila as a model organism for studying the complexity of
cancer.
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